After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.